Engineered PPM Enzymes for Ribonucleoside-to-Deoxyanalogue Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more effective compounds that inhibit HIV reverse transcriptase to ameliorate the effects of AIDS, as existing nucleoside analogues like MK-8591 face challenges in production due to their chemical complexity.
Innovation Solution
Engineered phosphopentomutase (PPM) enzymes with specific polypeptide sequences and substitutions are developed to enhance the production of pharmaceutical compounds that inhibit HIV reverse transcriptase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If standard chemical synthetic techniques are used to produce nucleoside analogues, then the compounds can be manufactured, but the production process becomes challenging due to chemical complexity
Solution Approach 1:
The patent changes the production approach from chemical synthesis to enzymatic synthesis, fundamentally altering the parameters of the manufacturing process. Engineered phosphopentomutase enzymes catalyze the conversion of ribonucleosides to deoxyribonucleoside analogues, transforming a chemically complex multi-step synthesis into a biologically simpler one-step enzymatic reaction, thereby resolving the contradiction between ease of manufacture and chemical complexity
Solution Approach 2:
The patent replaces the mechanical/chemical synthesis system with a biological enzymatic system. Instead of using chemical reagents, catalysts, and complex reaction conditions, the invention employs engineered phosphopentomutase enzymes to catalyze the formation of deoxyribonucleoside analogues, substituting a chemically complex process with a biologically-based process that is easier to manufacture
2Reliability
If existing nucleoside analogues like MK-8591 are used, then reverse transcriptase inhibition is achieved, but production efficiency is limited due to chemical complexity
Solution Approach 1:
The patent changes the production parameters by introducing engineered phosphopentomutase enzymes with optimized catalytic properties. These enzymes efficiently convert ribonucleoside substrates to deoxyribonucleoside analogues, dramatically improving production efficiency while maintaining the reliable reverse transcriptase inhibition effectiveness that characterizes compounds like MK-8591
Solution Approach 2:
The engineered phosphopentomutase enzymes are designed to self-catalyze the production of deoxyribonucleoside analogues without requiring complex chemical synthesis steps. The enzymes autonomously perform the conversion function, improving productivity while preserving the therapeutic effectiveness needed for reliable HIV reverse transcriptase inhibition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered PPM enzymes provide enhanced inhibition of HIV reverse transcriptase, addressing the limitations of existing nucleoside analogues by improving production efficiency and effectiveness.
Implementation Method 1
engineered phosphopentomutase (PPM) enzymes with specific polypeptide sequences and substitutions are developed to enhance the production of pharmaceutical compounds that inhibit HIV reverse transcriptase
Data Source
AI summary
The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.